Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine (Medis)
Primary Purpose
Chronic Migraine as Defined by Criteria of International Headache Society (IHS)
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Transcranial direct current stimulation of the motor cortex
simulation of Transcranial direct current stimulation of the motor cortex
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Migraine as Defined by Criteria of International Headache Society (IHS) focused on measuring Chronic migraine, tDCS, Transcranial direct current stimulation
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of chronic migraine for more than 1 year
- Stable treatment since 1 month
- Frequency of migraine crisis is above 8 per month during last month
- chronic migraine that has not been improved over the previous year by at least 3 different prophylactic treatments recommended and well conducted
- Patient agreeing not to try other migraine prophylactic treatment, throughout the study
- Patient's written consent
Exclusion Criteria:
- History of drug addiction, epilepsy, or severe head trauma with bone break
- History of psychiatric illness (psychosis and severe cognitive disorders) may interfere with the proper conduct of the study
- Presence of intracranial ferromagnetic material or an implanted stimulator
- Introduction of a new treatment for less than a month
- Pregnant women, parturient women, breast-feeding mother. Lack of effective contraception
- Person not understanding the study protocol
Sites / Locations
- Grenoble University Hospital
- Hospital of Voiron
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
active tDCS
simulated tDCS
Arm Description
Outcomes
Primary Outcome Measures
Comparison of the evolution of seizure frequency between the two groups
Secondary Outcome Measures
Comparison of the evolution of seizure severity between the two groups
Headache Impact Test 6 (HIT-6) questionnaire
Comparison of the evolution of crisis treatment use between the two groups
Frequency of taking crisis treatment. After each crisis, taking crisis treatment will be noted by the patient on his migraine record book.
Comparison of the evolution of the disease impact between the two groups
Migraine Disability Assessment Scale (MIDAS) scale
Comparison of the evolution of the patient satisfaction between the two groups
Clinical Global Impression (CGI) scale
Comparison of the evolution of the quality of life between the two groups
Short Form 12 (SF-12) quality of life questionnaire
Comparison of the evolution of anxiety and depression levels between the two groups
Hospital Anxiety and Depression scale (HAD) questionnaire
Full Information
NCT ID
NCT02120326
First Posted
April 15, 2014
Last Updated
November 3, 2020
Sponsor
University Hospital, Grenoble
1. Study Identification
Unique Protocol Identification Number
NCT02120326
Brief Title
Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine
Acronym
Medis
Official Title
Randomised Double-blind Evaluation of the Prophylactic Efficacy of Transcranial Direct Current Stimulation (tDCS) in Chronic Migraine
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
May 5, 2014 (Actual)
Primary Completion Date
December 18, 2019 (Actual)
Study Completion Date
June 23, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether TDCS is an effective prophylactic therapy of chronic migraine.
Detailed Description
Consenting patients will report on a book, all of their migraine attack for 1 month. Then they will be randomized to the active tDCS group or sham tDCS group. Patients will have one session of tDCS per day during the first week, then one session per week for a month and finally a session every 15 days for 1 month. After tDCS sessions, patients will be followed for 3 months. Throughout their participation in the study, patients will complete their migraine record (1month of base line before tDCS, 2 months during tDCS, 3 months after tDCS).
Patients will have 5 evaluation examinations:
The first, one before tDCS,
The second, 1 month after the beginning of tDCS
The third, immediately after the end of tDCS
The fourth, 1 month after the end of tDCS
And the last one, 3 months after the end of tDCS.
The physician responsible for conducting tDCS sessions will make the randomization via a website.
The physician in charge of the evaluation examinations will don't know the allocated treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Migraine as Defined by Criteria of International Headache Society (IHS)
Keywords
Chronic migraine, tDCS, Transcranial direct current stimulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
active tDCS
Arm Type
Experimental
Arm Title
simulated tDCS
Arm Type
Placebo Comparator
Intervention Type
Device
Intervention Name(s)
Transcranial direct current stimulation of the motor cortex
Intervention Description
The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.
Stimulation parameters:
2 mA intensity
Continuous stimulation for 20 min with rise times and fall times of 10 seconds each
Intervention Type
Device
Intervention Name(s)
simulation of Transcranial direct current stimulation of the motor cortex
Intervention Description
The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.
Stimulation parameters:
The intensity of the stimulation current is 2 mA
The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation.
Primary Outcome Measure Information:
Title
Comparison of the evolution of seizure frequency between the two groups
Time Frame
Evolution of seizure frequency since base line to 3 months after the end of tDCS
Secondary Outcome Measure Information:
Title
Comparison of the evolution of seizure severity between the two groups
Description
Headache Impact Test 6 (HIT-6) questionnaire
Time Frame
Evolution of seizure severity since base line to 3 months after the end of tDCS
Title
Comparison of the evolution of crisis treatment use between the two groups
Description
Frequency of taking crisis treatment. After each crisis, taking crisis treatment will be noted by the patient on his migraine record book.
Time Frame
Evolution of crisis treatment use since base line until 3 months after the end of tDCS
Title
Comparison of the evolution of the disease impact between the two groups
Description
Migraine Disability Assessment Scale (MIDAS) scale
Time Frame
Evolution of the disease impact since base line to 3 months after the end of tDCS
Title
Comparison of the evolution of the patient satisfaction between the two groups
Description
Clinical Global Impression (CGI) scale
Time Frame
Evolution of the patient satisfaction since base line to 3 months after the end of tDCS
Title
Comparison of the evolution of the quality of life between the two groups
Description
Short Form 12 (SF-12) quality of life questionnaire
Time Frame
Evolution of the quality of life since base line until 3 months after the end of tDCS
Title
Comparison of the evolution of anxiety and depression levels between the two groups
Description
Hospital Anxiety and Depression scale (HAD) questionnaire
Time Frame
Evolution of anxiety and depression levels since base line until 3 months after the end of tDCS
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of chronic migraine for more than 1 year
Stable treatment since 1 month
Frequency of migraine crisis is above 8 per month during last month
chronic migraine that has not been improved over the previous year by at least 3 different prophylactic treatments recommended and well conducted
Patient agreeing not to try other migraine prophylactic treatment, throughout the study
Patient's written consent
Exclusion Criteria:
History of drug addiction, epilepsy, or severe head trauma with bone break
History of psychiatric illness (psychosis and severe cognitive disorders) may interfere with the proper conduct of the study
Presence of intracranial ferromagnetic material or an implanted stimulator
Introduction of a new treatment for less than a month
Pregnant women, parturient women, breast-feeding mother. Lack of effective contraception
Person not understanding the study protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
HODAJ Hasan, MD
Organizational Affiliation
University Hospital, Grenoble
Official's Role
Principal Investigator
Facility Information:
Facility Name
Grenoble University Hospital
City
Grenoble
State/Province
Isere
ZIP/Postal Code
38043
Country
France
Facility Name
Hospital of Voiron
City
Voiron
State/Province
Isere
ZIP/Postal Code
38500
Country
France
12. IPD Sharing Statement
Learn more about this trial
Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine
We'll reach out to this number within 24 hrs